1-3 of 3
Peter Emanuel
Close
Sort by
Journal Articles

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

Clinical Trials & Observations
Jerald P. Radich, Kenneth J. Kopecky, Frederick R. Appelbaum, Suzanne Kamel-Reid, Wendy Stock, Greg Malnassy, Elisabeth Paietta, Martha Wadleigh, Richard A. Larson, Peter Emanuel, Martin Tallman, Jeff Lipton, A. Robert Turner, Michael Deininger, Brian J. Druker
Journal: Blood
Blood (2012) 120 (19): 3898–3905.
https://doi.org/10.1182/blood-2012-02-410688
Published: 2012
Journal Articles

Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results.

Azra Raza, MD, Natalie Callander, MD, Leonel Ochoa, MD, Lawrence Piro, MD, Peter Emanuel, MD, Susan Guba, MD, Gabriel Shapiro, MD, Stephanie Williams, MD, Howard Burris, III, MD, Stefan Faderl, MD, Zeev Estrov, MD, Peter Curtain, MD, Richard Larson, MD, Shelby Young, RN, Gail L. Brown, MD
Journal: Blood
Blood (2005) 106 (11): 2520.
https://doi.org/10.1182/blood.V106.11.2520.2520
Published: 2005
Journal Articles

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

Natalie Callander, MD, Jose L. Ochoa-Bayona, MD, Lawrence Piro, MD, Susan Guba, MD, Gabriel Shapiro, MD, Stephanie Williams, MD, Ira Oliff, MD, Howard Burris, III, MD, Anneliese Jameson, Kiran Patel, Gail L. Brown, MD, Stefan Faderl, MD, Zeev Estrov, MD, Peter Emanuel, MD
Journal: Blood
Blood (2004) 104 (11): 1428.
https://doi.org/10.1182/blood.V104.11.1428.1428
Published: 2004